Up to 25% of all DLBCL and FL cancers contain gain-of-function heterozygous mutations in the SET domain of EZH2 at tyrosine 641 (Y641) (Fig. 4; Morin et al. 2010). This evidence concerns the gene EZH2 and cancer.